Medication info
Exkressesba Tablets 5/160/5 mg

Exkressesba Tablets 5/160/5 mg

Prescription medicationTabletOral
Ingredient · strength
Amlodipine Besylate›6.94mg / 1 tabletValsartan›160mg / 1 tabletRosuvastatin Calcium›5.2mg / 1 tablet
Manufacturer / importer
Korea Hutech Pharmaceutical Co., Ltd.
Appearance
Pale yellow-pink oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202106228 · Approved 2021.08.27 · Insurance code 649105380

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease
Who takes it
Adults
Adult dose
Take 1 tablet of this medicine once daily with water. It is recommended that it be taken at the same time each day, if possible (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the doses of the individual components (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). Do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan must not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. Most patients are controlled with a maintenance dose of 10 milligrams once daily. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Ingredients

Manufacturer
Korea Hutech Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, inhibition of atherosclerosis, and prevention of cardiovascular disease

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is for patients who require treatment with a combination of amlodipine and valsartan for essential hypertension that cannot be adequately controlled, as well as those who need to treat hypercholesterolemia and dyslipidemia with rosuvastatin. Amlodipine/valsartan is effective for blood pressure control, and rosuvastatin lowers blood cholesterol and LDL-cholesterol levels, delaying the progression of atherosclerosis, and reducing the risk of cardiovascular diseases, strokes, myocardial infarction, and revascularization procedures. In other words, this medication is used to aid in blood pressure management and the prevention of cardiovascular diseases in patients with both hypertension and dyslipidemia.

How to take

Adult dose

Take 1 tablet of this medicine once daily with water. It is recommended that it be taken at the same time each day, if possible (e.g., before breakfast). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the amlodipine/valsartan combination and rosuvastatin. Patients taking an amlodipine/valsartan combination and rosuvastatin as separate products may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ▷ Amlodipine/valsartan combination Before administering the amlodipine/valsartan combination, it is recommended that the doses of the individual components (amlodipine or valsartan) be adjusted. However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to the amlodipine/valsartan combination may be considered as follows. ㆍ5/80 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 80 milligrams as monotherapy. ㆍ5/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or valsartan 160 milligrams as monotherapy. ㆍ10/160 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 10 milligrams or valsartan 160 milligrams as monotherapy, or with 5/160 milligrams. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment (creatinine clearance 10mL/min or higher). Do not administer the amlodipine/valsartan combination to patients with severe renal impairment (creatinine clearance below 10mL/min) or patients on dialysis. In patients with moderate renal impairment, monitoring of potassium levels and creatinine is recommended. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of valsartan must not exceed 80mg. Do not administer the amlodipine/valsartan combination to patients with severe hepatic impairment, biliary cirrhosis, biliary obstruction, or cholestasis. Elderly patients aged 65 years or older: Use caution when increasing the dose. ▷ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout treatment. Rosuvastatin may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to a maintenance dose. Most patients are controlled with a maintenance dose of 10 milligrams once daily. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, up to a maximum of 20 milligrams daily. 2. Elderly patients: No dosage adjustment is required. 3. Patients with renal impairment: No dosage adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of rosuvastatin is contraindicated in some of these patients.

Precautions

This medication should not be used during pregnancy, particularly in the second and third trimesters, as it can cause serious harm to the fetus; it must be discontinued immediately upon confirmation of pregnancy. Do not use this medication in women who are allergic to any component or who have severe liver dysfunction, severe renal impairment, or are pregnant or breastfeeding. Patients with a deficiency of sodium or fluid in the body, patients with hyperkalemia, and those with vascular issues in the kidneys should use this medication with particular caution, requiring careful monitoring by a physician. In patients with heart conditions such as heart failure or post-myocardial infarction, as well as patients with aortic stenosis, this medication should also be used cautiously due to the risk of side effects such as hypotension and vascular edema. If unusual symptoms like muscle pain, muscle weakness, or sudden muscle pain occur during the course of this medication, consult a doctor immediately, and it is advisable to regularly undergo liver function tests and blood tests. Caution is needed when driving or operating machinery as dizziness or fatigue may occur, particularly when starting this medication or changing dosages. Interactions may occur with other medications, so inform your physician or pharmacist about all medications currently being taken, particularly if taking potassium-sparing diuretics, potassium supplements, certain antibiotics, immunosuppressants, or fibrate medications. Women who are pregnant or breastfeeding should not take this medication and should use appropriate contraceptive methods if they are planning to become pregnant. The use of this medication is not recommended for children or adolescents under 18 years of age, as safety and efficacy have not been established. In elderly patients, bodily responses may be more sensitive, so it is advisable to start at a lower dosage and gradually adjust. In cases of overdose, serious hypotension, shock, and decreased heart function may occur, necessitating immediate medical attention.

Side effects

Peripheral edema, heat sensation, increased ALT, increased AST, increased serum creatinine, flank pain, neck pain, dizziness, sensory loss, nasopharyngitis, rash, nasopharyngitis, influenza, hypersensitivity, visual impairment, anxiety, headache, drowsiness, orthostatic dizziness, sensory abnormalities, lightheadedness, tinnitus, tachycardia, palpitations, syncope, orthostatic hypotension, hypotension, cough, sore throat and laryngeal pain, diarrhea, nausea, abdominal pain, constipation, thirst, erythema, sweating, rash, itching, joint edema, low back pain, arthritis, muscle cramps, lethargy, frequent urination, polyuria, erectile dysfunction, edema, abdominal edema, facial edema, fatigue, flushing, weakness, facial flushing, chest pain, pain, nocturia, chest discomfort, abdominal discomfort, gastroesophageal reflux disease, hypercholesterolemia, hypoglycemia, thrombocytopenia, leukopenia, allergic reaction, hyperglycemia, insomnia, mood changes, tremors, taste disturbance, peripheral neuropathy, hypertonia, arrhythmia, bradycardia, atrial fibrillation, ventricular tachycardia, vasculitis, dyspnea, rhinitis, vomiting, dyspepsia, pancreatitis, gastritis, gingival hyperplasia, hepatitis, jaundice, alopecia, purpura, skin depigmentation, photosensitivity, angioedema, urticarial, erythema multiforme, Stevens-Johnson syndrome, myalgia, urination disorder, nocturia, gynecomastia, pain, fatigue, weight loss, weight gain, hemoglobin decrease, hematocrit decrease, neutropenia, serum sickness, increased serum potassium, vasculitis, bullous dermatitis, myalgia, renal failure, kidney damage, increased serum creatinine, insomnia, decreased libido, pharyngitis, rhinitis, sinusitis, upper respiratory infection, viral infection, intestinal vascular edema, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, increased transaminases, eosinophilia, drug reaction with systemic symptoms syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, headache, increased ALT, chest pain, myalgia, increased CK, constipation, weakness, joint pain, fatigue, numbness, sensory abnormalities, chest discomfort, loss of appetite, abdominal distension, abnormal liver function tests, syncope, generalized pain, muscle cramps, gout, erectile dysfunction, acute renal failure, oliguria, increased serum creatinine

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to protect it from exposure to air and moisture. It is advisable to maintain storage temperatures between 1 and 30 degrees Celsius (room temperature).

Appearance and packaging

Appearance

Pale yellow-pink oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.